Thus, the relationships in DLBCL suggest that FGL2 may provide an additional element of negative feedback and adaptive immune resistance, which is potentially suitable for therapeutic targeting [72, 73]. This evidence concerns the gene FGL2 and diffuse large B-cell lymphoma.